HLA-C and cancer: In contrast to expressing different engineered CARs on a single T cell, cancer patients could be transfected with a combination of different T cells expressing unique, engineered TCRs, each recognizing a single neoantigen peptide/MHC estimated previously using a personalized library of soluble predicted neoantigen–HLA capture reagents [31].